How did RMTI's Q1 2025 EPS forecast compare to past trends?

Rockwell Medical's (RMTI) Q1 2025 EPS forecast is not currently available. However, the latest available data shows that RMTI's EPS has been negative in the past few quarters with significant losses in Q4 2022 and Q3 2023, but improved to profitability in Q4 2024.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|RMTI|RMTI.O|Rockwell Medical|2022 Q1|7.692307692307699|-0.84|186|
|RMTI|RMTI.O|Rockwell Medical|2022 Q2|56.565656565656575|-0.43|186|
|RMTI|RMTI.O|Rockwell Medical|2022 Q3|74.15730337078652|-0.23|186|
|RMTI|RMTI.O|Rockwell Medical|2023 Q1|88.09523809523809|-0.1|186|
|RMTI|RMTI.O|Rockwell Medical|2023 Q2|58.139534883720934|-0.18|186|
|RMTI|RMTI.O|Rockwell Medical|2023 Q3|69.56521739130434|-0.07|186|
|RMTI|RMTI.O|Rockwell Medical|2024 Q1|40.00000000000001|-0.06|186|
|RMTI|RMTI.O|Rockwell Medical|2024 Q2|105.55555555555556|0.01|186|
|RMTI|RMTI.O|Rockwell Medical|2024 Q3|157.14285714285714|0.04|186|

The company's financial performance has shown a significant improvement, reporting record net sales and gross profit for the third year in a row, with net sales reaching $101.5 million in 2024, a 21% increase from the previous year. Despite the positive trends, the company anticipates a transition year in 2025 with challenges, including the loss of its largest customer, expected to result in an estimated $34 million reduction in revenue. Therefore, the EPS forecast for Q1 2025 may be impacted by these factors.